CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, is presenting data today at the 2007 RBC Capital Markets Healthcare Conference on The Pharmaceutical Sweet Spot: Diabetes And Obesity Treatments Panel demonstrating that one of its new chemical entity (NCE) SIRT1 activators lowers plasma glucose and improves insulin sensitivity in a pre-clinical model of Type 2 Diabetes as well as or better than sitagliptin, a DPP-4 inhibitor. In addition, in an intraperitoneal glucose tolerance test, Sirtris’ SIRT1 activator was shown to control glucose excursion as well as sitagliptin in this pre-clinical model of Type 2 Diabetes. In contrast to DPP-4 inhibitors, which lower glucose, SIRT1 activation appears to both lower glucose and also sensitize to insulin in these models.
